MedTrace Logo

Preliminary Study of Piclozotan in Patients With Motor Complications Associated With Parkinson's Disease

NCT00623363 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 27

Last updated 2021-03-11

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to obtain preliminary information on the effect of piclozotan on motor complications associated with Parkinson's Disease.

Conditions

Interventions

DRUG

piclozotan

piclozotan, intravenous (IV) infusion

DRUG

0.9% sodium chloride (normal saline)

0.9% sodium chloride (normal saline) intravenous (IV) infusion

Sponsors & Collaborators

Principal Investigators

  • Global Clinical Leader · Daiichi Sankyo

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-07-13
Primary Completion
2008-07-17
Completion
2008-07-17
FDA Drug
Yes

Countries

  • United States
  • Guatemala
  • Romania

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00623363 on ClinicalTrials.gov